For: | Castellote J, Ariza J, Rota R, Girbau A, Xiol X. Serious drug-induced liver disease secondary to ezetimibe. World J Gastroenterol 2008; 14(32): 5098-5099 [PMID: 18763297 DOI: 10.3748/wjg.14.5098] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v14/i32/5098.htm |
Number | Citing Articles |
1 |
Željko Reiner. Management of patients with familial hypercholesterolaemia. Nature Reviews Cardiology 2015; 12(10): 565 doi: 10.1038/nrcardio.2015.92
|
2 |
M V. Zykov. The problem of safety of lipid-lowering therapy. Kardiologiia 2019; 59(5S): 13 doi: 10.18087/cardio.2505
|
3 |
Rgia A. Othman, Semone B. Myrie, David Mymin, Louise S. Merkens, Jean-Baptiste Roullet, Robert D. Steiner, Peter J.H. Jones. Ezetimibe Reduces Plant Sterol Accumulation and Favorably Increases Platelet Count in Sitosterolemia. The Journal of Pediatrics 2015; 166(1): 125 doi: 10.1016/j.jpeds.2014.08.069
|
4 |
Firas J. Al Badarin, Iftikhar J. Kullo, Stephen L. Kopecky, Randal J. Thomas. Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. Mayo Clinic Proceedings 2009; 84(4): 353 doi: 10.1016/S0025-6196(11)60545-4
|
5 |
Keshav Kumar Gupta, Shair Ali, Ranjodh Singh Sanghera. Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. Cardiology and Therapy 2019; 8(1): 5 doi: 10.1007/s40119-018-0123-0
|
6 |
Yoonkyung Chang, Soojeong Eom, Minjeong Kim, Tae-Jin Song. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. Medicina 2023; 59(4): 776 doi: 10.3390/medicina59040776
|
7 |
Dina Halegoua-De Marzio, Victor J. Navarro. Drug-Induced Liver Disease. 2013; : 519 doi: 10.1016/B978-0-12-387817-5.00029-7
|
8 |
Venice Du Pont, Richard K Plemper, Matthias J Schnell. Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. Current Opinion in Virology 2019; 35: 1 doi: 10.1016/j.coviro.2018.12.009
|
9 |
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 2009; 18(2) doi: 10.1002/pds.1645
|
10 |
Firas J. Al Badarin, Iftikhar J. Kullo, Stephen L. Kopecky, Randal J. Thomas. Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. Mayo Clinic Proceedings 2009; 84(4): 353 doi: 10.4065/84.4.353
|
11 |
Željko Reiner. Combined therapy in the treatment of dyslipidemia. Fundamental & Clinical Pharmacology 2010; 24(1): 19 doi: 10.1111/j.1472-8206.2009.00764.x
|
12 |
Ryan C. Van Woerkom, Douglas G. Adler. Letter to the Editor. Journal of Clinical Lipidology 2010; 4(4): 314 doi: 10.1016/j.jacl.2010.03.075
|
13 |
Michael Demyen, Kawtar Alkhalloufi, Nikolaos T. Pyrsopoulos. Lipid-Lowering Agents and Hepatotoxicity. Clinics in Liver Disease 2013; 17(4): 699 doi: 10.1016/j.cld.2013.07.016
|
14 |
Retrospective Study on Hepatic Injury of Ezetimibe and Simvastatin Combination vs. Simvastatin. Journal of Korean Society of Health-System Pharmacists 2013; 30(6): 523 doi: 10.32429/jkshp.2013.30.6.002
|
15 |
Tharsan Kanagalingam, Julieta Lazarte, David K.H. Wong, Robert A. Hegele. Liver Injury Associated With Ezetimibe Monotherapy. CJC Open 2021; 3(2): 195 doi: 10.1016/j.cjco.2020.09.018
|
16 |
Silje Bergland Ellingsen, Elisabet Nordmo, Knut Tore Lappegård. Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination With Ezetimibe. Clinical Medicine Insights: Case Reports 2017; 10 doi: 10.1177/1179547617731375
|
17 |
Fawaz Almutairi, Theresa C. Peterson, Michele Molinari, Mark J. Walsh, Ian Alwayn, Kevork M. Peltekian. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transplantation 2009; 15(5): 504 doi: 10.1002/lt.21710
|